Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer.

Trial Profile

Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms SubDueP
  • Most Recent Events

    • 27 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 15 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top